Fasting glucose improved within weeks and my HbA1c barely moved for three months, which I now understand and did not at the time.
Because it is glucose-dependent, this class carries a low intrinsic hypoglycaemia risk on its own — the risk arrives when it is combined with insulin or a sulfonylurea, which usually need reducing.
The question I want answered is why A1C lags the way it does, and what to look at in the meantime if you want to know sooner.
I have searched first, so if this is covered somewhere point me at it and I will read it.
mel_PDX said:Fasting glucose improved within weeks and my HbA1c barely moved for three months, which I now understand and did not at the time.
My labs after 6 months on glycaemic control: A1C 5.5%, fasting glucose 80 mg/dL, fasting insulin 9 uIU/mL. My endo says these are "textbook perfect."
For context, my baseline A1C was 7.5% and fasting glucose was 115 mg/dL. The improvement has been dramatic and consistent.
NurseKim_ATL said:My labs after 6 months on glycaemic control: A1C 5.5%, fasting glucose 80 mg/dL, fasting insulin 9 uIU/mL.
PCOS success story with glycaemic control: as someone with polycystic ovary syndrome, this medication has been transformative beyond weight loss.
After 11 months: periods became regular for the first time in a decade, testosterone levels normalized, acne cleared significantly, and — unexpectedly — my fertility specialist is optimistic about future conception.
GLP-1 agonists address the insulin resistance at the root of PCOS. For PCOS patients, this isn't "just" a weight loss drug — it's treating our underlying metabolic dysfunction.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference Standardsmel_PDX said:Fasting glucose improved within weeks and my HbA1c barely moved for three months, which I now understand and did not at the time.
Same experience, arrived at from the opposite direction.
Adding the clinical framing, because it changes how the question reads.
Patient selection optimization for glycaemic control: emerging predictive biomarkers for GLP-1 agonist response include:
| Biomarker | Association | Evidence Level |
|---|---|---|
| Baseline BMI | Higher BMI → greater absolute weight loss | Strong |
| Fasting insulin | Higher insulin → better response | Moderate |
| GLP1R gene variants | rs6923761 → variable response | Preliminary |
| Baseline hsCRP | Higher CRP → greater CV benefit | Moderate |
| Early weight loss (4 wk) | ≥3% at 4 wks → strong predictor of ≥10% at 68 wks | Strong |
The 4-week early responder criterion is the most clinically actionable: if you haven't lost ≥3% by week 4 at a therapeutic dose, discuss optimization strategies with your provider.